The European Hematology Association is organizing its 30th EHA Congress, taking place in Milan from June 12–15, 2025, EHA2025. Focus of this years' congress is cutting-edge evidence-based approaches to diagnosis and treatment, highly anticipated clinical and translational research data and the newest developments in innovative techniques, diagnostic tools, and risk-assessment strategies. EHA2025 knows no bounds and is intended for medical professionals, national hematology societies, patient groups, medical industry, and media worldwide.
SYNTHIA Partners working in the two use cases Multiple Myeloma and Diffuse large B-cell Lymphoma will particpate in EHA2025.
Would you like to connect on site? Email Ellen de Waal, SYNTHIA Lead Communiations at e.dewaal@matical.com
SYNTHIA is addressing these challenges head-on by developing validated tools and methods for synthetic data generation (SDG) across various data types, including laboratory results, clinical notes, genomics and imaging. By focusing on six specific diseases - use cases - SYNTHIA will demonstrate the utility of synthetic data in advancing personalized medicine of which are two blood cancers: Multiple myeloma, Diffuse large B-cell lymphoma.
